Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed-Refractory Chronic Lymphocytic LeukemiaReport as inadecuate




Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed-Refractory Chronic Lymphocytic Leukemia - Download this document for free, or read online. Document in PDF available to download.

Advances in HematologyVolume 2009 2009, Article ID 547582, 4 pages

Clinical Study

Department of Hematology, Singapore General Hospital, Singapore 169608

Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore 169547

CLL Unit, Royal Marsden Hospital, London SW3 6JJ, UK

Received 8 September 2008; Accepted 15 December 2008

Academic Editor: Luen Bik To

Copyright © 2009 William Y. K. Hwang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Intravenous alemtuzumab and fludarabine are effective in combination for the treatment of chronic lymphocytic leukemia CLL, but require hospital visits for intravenous injection. We performed a pilot study to assess the safety and efficacy of outpatient-based oral fludarabine with subcutaneous alemtuzumab OFSA for the treatment of relapsed-refractory CLL. Results. Depending on their response, patients were given two to six 28-day cycles of subcutaneous alemtuzumab 30 mg on days 1,3, and 5 and oral fludarabine 40 mg- m 2 -day for 5 days. Median patient age was 74. The lymphocyte counts of all five patients fell after the 1st cycle of treatment and reached normal-low levels on completion of 2 to 6 cycles of therapy. Platelet counts and hemoglobin were unaffected. All five patients achieved complete hematological remission, while two attained minimal residual disease negativity on 4-color flow cytometry. Conclusions. Our OFSA regimen was effective in elderly Asian patients with relapsed-refractory CLL, and it should be investigated further.





Author: William Y. K. Hwang, Claire Dearden, Yvonne S. M. Loh, Yeh C. Linn, Sim L. Tien, Gerrard K. H. Teoh, Gee F. How, Kee K. Hen

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents